Jump to content
Pharmacy PT-141

A card catalogue of desire, side effects and mistaken identity.

The reference shelf

PT-141 references: FDA approval, interactions and Europe.

PT-141 references for bremelanotide FDA approval and drug interactions. The reading list also states what it cannot establish about Europe and EMA approval.

Bremelanotide FDA approval: the dated label card.

PT-141’s regulatory entry is the U.S. bremelanotide prescribing information. FDA approved bremelanotide on June 21, 2019, for acquired, generalized HSDD in premenopausal women. The first-approval review gives the development and indication context, while the Phase 3 trial report supplies the pivotal desire and distress results.

These are the documents I’d open before a general account of peptide approvals. The label defines the approved product and use. It does not approve research-labelled powder or a compounded preparation, and it does not cover men, postmenopausal women or enhanced sexual performance.

Bremelanotide drug interactions: “minimal” carries a caveat.

The LiverTox monograph describes minimal drug–drug interactions. A general interactions summary leaves individual combinations unevaluated. The prescribing information remains the product-specific document, with cardiovascular contraindications and warnings that a general interactions summary cannot replace.

The source shelf also includes a Phase I study of bremelanotide coadministered with ethanol in healthy male and female participants. Its population and study setting matter. I’m cautious about a combination studied under observation being retold as permission for every combination outside it.

Bremelanotide in Europe: does this record establish EMA approval?

The regulatory approval documented here is U.S. FDA approval. None of the entries in this list establishes an EMA authorization or a European approval for bremelanotide. A U.S. decision cannot answer the European question.

I leave that entry unresolved rather than fill it with an assumed yes or no. These references do not support a claim about European availability or legality. The first-approval review records the U.S. milestone; the reference supplied here concerns that U.S. decision.

The shelf has studies, histories and appraisals.

The female-rat solicitation paper, human brain-imaging study and Syrian hamster reward study describe different populations and outcomes. The historical melanocortin review explains where the story began. Dates separate older therapeutic perspectives from later approval records; forensic analysis asks a different question about product quality.

I like having those unlike documents close together. Their differing questions and conclusions make the shelf more interesting. The full reading list follows, including sources used for safety, pharmacokinetics and remote-care context.

  1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. ↗
  2. Pfaus J, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101:10201-10204. ↗
  3. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. ↗
  4. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. ↗
  5. Thurston L, Hunjan T, Mills EG, Wall MB, Ertl N, Phylactou M, Muzi B, Patel B, Alexander EC, Suladze S, Modi M, Eng PC, Bassett PA, Abbara A, Goldmeier D, Comninos AN, Dhillo WS. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Clin Invest. 2022;132(19):e152341. ↗
  6. Borland JM, Kohut-Jackson AL, Peyla AC, Hall MA, Mermelstein PG, Meisel RL. Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. Neuropharmacology. 2025;267:110299. ↗
  7. U.S. Food and Drug Administration / DailyMed. Bremelanotide Injection — US Prescribing Information. DailyMed (US FDA structured product label). 2019. ↗
  8. Dooley AB, Houssaini AS, Tsai T, Ramasamy R. Use of Telemedicine for Sexual Medicine Patients. Sex Med Rev. 2020;8(4):507-517. ↗
  9. Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Medical Treatment of Female Sexual Dysfunction. Urol Clin North Am. 2022. ↗
  10. Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2020;13(3):40. ↗
  11. Gelman F, Atrio J. Flibanserin for hypoactive sexual desire disorder: place in therapy. Ther Adv Chronic Dis. 2017. ↗
  12. Hellstrom WJ. Clinical applications of centrally acting agents in male sexual dysfunction. Int J Impot Res. 2008. ↗
  13. Pyke RE, Clayton AH. Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. Sex Med Rev. 2018. ↗
  14. Shadiack AM, Althof S. Preclinical effects of melanocortins in male sexual dysfunction. Int J Impot Res. 2008. ↗
  15. Tan R, et al. Telemedicine Use During the COVID-19 Pandemic in 8 Countries From the International Society for Sexual Medicine. J Med Internet Res. 2025. ↗
  16. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79:1599-1606. ↗
  17. White WB, Myers MG, Jordan R, Lucas J. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017;35(4):761-768. ↗
  18. Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017;39(3):514-526.e14. ↗
  19. Clayton AH, Kingsberg SA, Portman D, Sadiq A, Jordan R, Lucas J, Spana C, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182. ↗
  20. National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox). Bremelanotide - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (LiverTox). 2021. ↗
  21. Mestria S, Odoardi S, Frison G, Strano Rossi S. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs.. Drug testing and analysis. 2021. ↗
  22. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.. Clinical toxicology (Philadelphia, Pa.). 2012. ↗
  23. Spana C, Jordan R, Fischkoff S. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes Obes Metab. 2022;24(6):1084-1093. ↗
  24. Bardhan M, Anand A, Javed A, Chilo MA, Khan N, Garg T. Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.. Diseases (Basel, Switzerland). 2025. ↗
  25. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.. Peptides. 2006. ↗
  26. Hedlund P. PT-141 Palatin.. Current opinion in investigational drugs (London, England : 2000). 2004. ↗